Your browser doesn't support javascript.
The landscape of antibody binding affinity in SARS-CoV-2 Omicron BA.1 evolution.
Moulana, Alief; Dupic, Thomas; Phillips, Angela M; Chang, Jeffrey; Roffler, Anne A; Greaney, Allison J; Starr, Tyler N; Bloom, Jesse D; Desai, Michael M.
  • Moulana A; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, United States.
  • Dupic T; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, United States.
  • Phillips AM; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, United States.
  • Chang J; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, United States.
  • Roffler AA; Department of Physics, Harvard University, Cambridge, United States.
  • Greaney AJ; Biological and Biomedical Sciences, Harvard Medical School, Boston, United States.
  • Starr TN; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, United States.
  • Bloom JD; Department of Genome Sciences, University of Washington, Seattle, United States.
  • Desai MM; Medical Scientist Training Program, University of Washington, Seattle, United States.
Elife ; 122023 02 21.
Artigo em Inglês | MEDLINE | ID: covidwho-2273020
ABSTRACT
The Omicron BA.1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal antibodies that are effective against earlier strains of the virus. This immune evasion is largely a consequence of mutations in the BA.1 receptor binding domain (RBD), the major antigenic target of SARS-CoV-2. Previous studies have identified several key RBD mutations leading to escape from most antibodies. However, little is known about how these escape mutations interact with each other and with other mutations in the RBD. Here, we systematically map these interactions by measuring the binding affinity of all possible combinations of these 15 RBD mutations (215=32,768 genotypes) to 4 monoclonal antibodies (LY-CoV016, LY-CoV555, REGN10987, and S309) with distinct epitopes. We find that BA.1 can lose affinity to diverse antibodies by acquiring a few large-effect mutations and can reduce affinity to others through several small-effect mutations. However, our results also reveal alternative pathways to antibody escape that does not include every large-effect mutation. Moreover, epistatic interactions are shown to constrain affinity decline in S309 but only modestly shape the affinity landscapes of other antibodies. Together with previous work on the ACE2 affinity landscape, our results suggest that the escape of each antibody is mediated by distinct groups of mutations, whose deleterious effects on ACE2 affinity are compensated by another distinct group of mutations (most notably Q498R and N501Y).
Assuntos
Palavras-chave

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Estudo experimental / Ensaios controlados aleatorizados Tópicos: Variantes Limite: Humanos Idioma: Inglês Ano de publicação: 2023 Tipo de documento: Artigo País de afiliação: ELife.83442

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Estudo experimental / Ensaios controlados aleatorizados Tópicos: Variantes Limite: Humanos Idioma: Inglês Ano de publicação: 2023 Tipo de documento: Artigo País de afiliação: ELife.83442